

News Release

Seeing Cell to Cell Differences for First Time Explains Symptoms of Rare Genetic Disorders, Finds Penn Study

Every cell in the body has two genomes, one from the mother and one from the father. Until now, researchers have lacked the tools to examine -- in a single cell --the exact readout from each genome to make RNA.

April 01, 2016

PHILADELPHIA -- Every cell in the body has two genomes, one from the mother and one from the father. Until now, researchers have lacked the tools to examine -- in a single cell --the exact readout from each genome to make RNA. Using a new technology that allows researchers to do just that, an interdisciplinary **University of Pennsylvania** team examined a rare disease in which these two genomes are expressed differently throughout the body, even sometimes in the same organ. They found that at the single-cell level gene expression was highly variable and quite different than expected, which is now shedding light on the molecular causes of rare diseases and perhaps the complex nature of tumors.



“This is a great example of cross-school collaboration,” said co-senior author **Marisa Bartolomei, PhD**, a professor of Cell and Developmental Biology in the **Perelman School of Medicine**. Her colleagues are co-first author **Jennifer M. Kalish, MD, PhD**, an expert in rare growth disorders from The Children’s Hospital of Philadelphia, and co-first author **Paul Ginart**, an MD/PhD candidate, and co-senior author **Arjun Raj, PhD**, both from the School of Engineering and Applied Science at Penn, who devised the technology to image single genes in individual cells. The team published their findings in *Genes & Development*.

“With this new technique, we can now see which cells express which genome,” Bartolomei said.

Epigenetic mosaicism occurs during development in a mouse model of a rare disease.

Credit: Connie Jiang, MD/PhD student, Perelman School of Medicine, University of Pennsylvania

Silence of the Genes

For most genes, people inherit two copies, one maternal and one paternal. However, in the case of a phenomenon called imprinting, offspring inherit only one working copy of a gene, and depending on its parental origin, expression of the gene is controlled by an added methyl group during egg or sperm formation to physically tighten DNA so it cannot be read to make RNA and ultimately protein.

A small number of genes are imprinted but are critical to normal development. Imprinted genes are normally turned on from either the maternal chromosome *or* the paternal chromosome, but not both. In human imprinting disorders, imprinted genes are either abnormally *turned on for both* the maternal and paternal genomes, or abnormally *turned off from both* genomes. Abnormal expression can be linked to genetic mutations and mistakes in the placement of the methyl group (a function of epigenetics).

Variability from cell to cell in which genes are expressed in the same organ may help explain why many diseases show a “mosaic” pattern, with different parts of the body exhibiting different degrees of disease. This hodge-podge can happen because of errors in imprinting.

Defects in imprinting can lead to inappropriate expression of the normally silenced version of the gene, but it remains unclear whether every cell in a given organ expresses the abnormal version. “If this were the case, it would have profound implications for human imprinting disorders,” Kalish said.

Help from the Rare

Imprinting disorders are rare. Kalish works with two: Russell-Silver syndrome, an under growth disorder occurring in approximately 1 out of 50,000 to out of 100,000 births, with symptoms of small stature and limb, body, or facial asymmetry. The syndrome involves under-methylation of two genes, *H19* and *IGF2*. *H19* encodes a non-coding RNA that limits growth whereas *IGF2* is a growth factor. In 50 percent of cases, Russell-Silver syndrome is associated with an imprinting error on chromosome 11 in which the person receives two copies of the imprinting mark from the mother rather than one from each parent. Russell-Silver children have too much of the do-not-grow signal (*H19*) and too little of the grow signal (*IGF2*). The other imprinting disorder is Beckwith-Wiedemann syndrome, an overgrowth disorder usually present at birth, characterized by an increased risk of childhood cancer and such congenital features as a large tongue, large birth weight, and limb, body, organ, and facial asymmetry.

These syndromes display a range of symptoms, which happens because some cells in a given organ express maternal genes while others express paternal genes. “But the mom genes are the ones that limit growth of cells,” Kalish said. “This means that the mosaic pattern is really a mix of normal cells and abnormal cells -- with a disrupted balance between mom’s do-not-grow signals and dad’s grow signals, in the same tissue. This is what accounts for an enlarged or too-small organ in the same person.” In some cases, patients may even have differently sized pairs of kidneys.

Using mice, the team compared cell genomes in normal mice versus Russell-Silver syndrome mice. At the cell population level, they asked which individual cells have correct maternal imprinting and which cells have abnormal maternal imprinting for the *H19* gene. In Russell-Silver mice both maternal and paternal *H19* is expressed.

Using Raj’s new technology, they developed a molecular probe to detect a single nucleotide change in the RNA expressed in mom’s versus dad’s genomes to show which is expressed cell by cell. This method measured gene-variant specific expression in single cells. In the mouse model of Russell-Silver syndrome, they found that some cells had RNA from both the maternal and paternal version (abnormal—as seen in Russell-Silver patients) while other cells had only the maternal RNA (normal).

“We showed that mutant mouse embryo fibroblast cells are comprised of two subpopulations: those expressing both maternal and paternal *H19* versions [abnormal] and those expressing only the maternal copy [normal],” Bartolomei said. “Only in the latter normal cell population is *Igf2* expression detected.”

In the Russell-Silver mice, all cells had the same genetic change but not all cells had the same DNA methylation pattern, explaining the mosaic arrangement of gene expression by epigenetics -- the normal silencing of a version of a gene by the added methyl group during egg or sperm formation.

The two mutant subpopulations of cells exhibited distinct methylation patterns at the imprinting control region of their respective genomes. The cells that expressed *H19* from just the maternal genome had the correct DNA methylation pattern while the cells that expressed *H19* from both maternal and parental genomes exhibited a loss of *H19* DNA methylation. Importantly, they also observed the same two subpopulations are also present within mouse heart tissue, showing the same defect in a living whole mouse.

“This is the first time that epigenetic mosaicism has been demonstrated at a single cell level,” Bartolomei said. “What this means is that epigenetics -- the balance of tightening or loosening of DNA to control which genes are expressed when -- is the driver of mosaicism at the cell population level. Our results establish that imprinting disorders can display striking single-cell heterogeneity and suggest that such heterogeneity may underlie epigenetic mosaicism in human imprinting disorders,” Bartolomei said.

“The epigenetic mosaicism shown in this work explains the spectrum of clinical features we see in our patients -- it all makes sense,” Kalish said. “Now we know what is going on.”

Other Penn coauthors are Connie L. Jiang and Alice C. Yu.

This study was funded by the National Institutes of Health (1R33EB019767, KL2TR000139, K08CA193915, GM051279), Alex’s Lemonade Stand Foundation, the St. Baldrick’s Foundation, an NIH Director’s New Innovator award (1DP2OD008514), a Burroughs-Wellcome Fund Career Award at the Scientific Interface, and the National Science Foundation (1350601, U01HL129998).

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a \$7.8 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with \$405 million awarded in the 2017 fiscal year.

The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided \$500 million to benefit our community.

Contacts

Karen Kreeger

C: 215-459-0544

O: 215-349-5658

For Patients and the General Public:

1-800-789-7366

